{"doi":"10.1021/jm801154q","title":"Effect of Fluorination on the Pharmacological Profile of 11β Isomers of Fulvestrant in Breast Carcinoma Cells","abstract":null,"journal":"Journal of Medicinal Chemistry","year":2009,"id":639016,"datarank":0.38474240361923057,"base_score":2.5649493574615367,"endowment":2.5649493574615367,"self_citation_contribution":0.38474240361923057,"citation_network_contribution":0.0,"self_endowment_contribution":0.38474240361923057,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":12,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1660009,"name":"Emmanuel Magnier","orcid":null,"position":1,"is_corresponding":false},{"id":1660010,"name":"Jean-Claude Blazejewski","orcid":null,"position":2,"is_corresponding":false},{"id":1660011,"name":"Ioanna Laïos","orcid":null,"position":3,"is_corresponding":false},{"id":1660012,"name":"Anny Cleeren","orcid":null,"position":4,"is_corresponding":false},{"id":1660013,"name":"Denis Nonclercq","orcid":null,"position":5,"is_corresponding":false},{"id":1558738,"name":"Guy Laurent","orcid":null,"position":6,"is_corresponding":false},{"id":1660014,"name":"Guy Leclercq","orcid":null,"position":7,"is_corresponding":false},{"id":1660008,"name":"Vangelis Agouridas","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Effect of Fluorination on the Pharmacological Profile of 11β Isomers of Fulvestrant in Breast Carcinoma Cells","abstract":"We describe the synthesis of an 11beta isomer 3 of the steroidal antiestrogen fulvestrant 2. Partial fluorination of the 11beta side chain in 3 leads to 4, which still shows strong antiproliferative activity on MCF-7 cells. However, unlike 2 and 3, compound 4 fails to down-regulate estrogen receptor alpha (ERalpha). This result suggests that ERalpha down-regulation is not a sine qua non condition for the antitumor activity of steroidal antiestrogens.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19133777","pmcid":null,"openalex_id":null,"authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://pubs.acs.org/doi/pdf/10.1021/jm801154q","host_type":"publisher"}],"fields_of_study":[],"mesh_terms":["Cell Line, Tumor","Humans","Breast Neoplasms","Estradiol","Estrogen Receptor Modulators","Estrogen Receptor alpha","Antineoplastic Agents","Down-Regulation","Fulvestrant"],"keywords":[],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T22:14:14.445883Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}